Article Publish Status: FREE
Abstract Title:

Effect ofBNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial.

Abstract Source:

Food Sci Biotechnol. 2018 Jun ;27(3):853-857. Epub 2017 Dec 12. PMID: 30263811

Abstract Author(s):

Ji Yeon Kim, Yeo Jin Park, Hyo Jin Lee, Min Young Park, Oran Kwon

Article Affiliation:

Ji Yeon Kim


BNR17 is a strain isolated from human breast milk. The objective of this randomized, double-blind, placebo-controlled, and preliminary dose-finding trial was to find the effective dose and evaluate the effect ofBNR17 on irritable bowel syndrome (IBS) symptoms. A total of 55 volunteers aged over 20 years with body mass index over 23 kg/mwere randomized to intake a placebo, low-dose (BNR-L, 2 × 10 CFU/day), intermediate-dose (BNR-M, 2 × 10 CFU/day), or high-dose BNR (BNR-H, 2 × 5 × 10 CFU/day) for four weeks. Questionnaire for IBS symptoms scores andBNR17 in feces were assessed at the beginning and end of the trial. Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group.BNR17 was detected in all intake groups except placebo. In the preliminary study,BNR17 was confirmed to have probiotic properties.

Study Type : Human Study

Print Options

Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.